Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day

Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands

Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range

DUBLIN, May 7, 2025 /PRNewswire/ --

First Quarter 2025 Highlights:

• Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested businesses, exited product lines and currency translation.
• Organic¹ net sales decreased 0.4% as higher net sales in the Nutrition, Upper Respiratory and Healthy Lifestyle categories were more than offset by previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%, the lack of a prior year benefit in the Women's Health category of 1.4% from initial retailer stocking of Opill^® which launched at the end of the quarter, and lower net sales in the Digestive Health category.
• Excluding previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%, and the lack of a prior year benefit in the Women's Health category of 1.4% from initial retailer stocking of Opill^®, organic net sales grew 1.8%.
• Consumer Self-Care International ("CSCI") net sales of $423 million declined 3.4% compared to the prior year quarter, including an unfavorable impact of 7.9% from divested businesses, exited product lines and currency translation. CSCI organic net sales grew 4.5% due primarily to growth in the Upper Respiratory, Pain and Sleep Aids and Healthy Lifestyle categories.
• Consumer Self-Care Americas ("CSCA") net sales of $621 million were down 3.6% compared to the prior year quarter as higher net sales in the Nutrition and Upper Respiratory categories were more than offset by previously disclosed net lost distribution of lower margin products of 1.3%, the lack of a prior year benefit in the Women's Health category of 2.3% from initial retailer stocking of Opill^® which launched at the end of the prior year quarter, and lower net sales in the Digestive Health category.
• GAAP ("reported") gross margin was 37.6%, an increase of 450 basis points compared to the prior year quarter. Non-GAAP ("adjusted") gross margin expanded 440 basis points to 41.0% driven primarily by infant formula business recovery and the Company's Supply Chain Reinvention program.
• Reported operating income was $47 million compared to a loss of $(55) million in the prior year quarter. Adjusted operating income of $147 million increased $54 million, or 57.6%, compared to the prior year period due primarily to infant formula business recovery and benefits from 'Project Energize' (see "Project Energize" section below for details).
• Reported operating margin was 4.5%, an increase of 960 basis points compared to the prior year quarter. Adjusted operating margin expanded 550 basis points to 14.0% driven primarily by adjusted gross margin expansion and benefits from Project Energize.
• Reported diluted earnings per share ("EPS") were breakeven in the first quarter 2025, compared to reported diluted EPS of $0.03 in the prior year quarter.
• Adjusted diluted EPS of $0.60, compared to $0.29 in the prior year quarter, increased $0.31, or 106.9%, per share, driven by the increase in adjusted operating income and lower interest expense due to lower total debt outstanding. First quarter 2025 adjusted diluted EPS included a higher tax rate compared to the prior year equating to $0.03 per adjusted diluted share, in addition to an impact from divested businesses, exited product lines and currency translation of $0.04 per adjusted diluted share.

Fiscal Year 2025 Outlook:

• The Company widened its fiscal 2025 outlook for reported net sales growth to 0% to 3% from 1% to 3% and organic net sales growth to 1.5% to 4.5% from 2.5% to 4.5%. The Company reaffirmed all other 2025 financial targets, including adj. EPS. This outlook includes known impacts from marcroeconomic uncertainty, including tariffs (see "Known Impacts from Macroeconomic Uncertainty" section below for details).

Perrigo Company plc (NYSE:PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended March 29, 2025 of fiscal year 2025. All comparisons are against the prior year first quarter, unless otherwise noted.

President and CEO Patrick Lockwood-Taylor commented, "We advanced our 'Three-S' Plan to Stabilize, Streamline, and Strengthen Perrigo as Stabilization and recovery efforts in our infant formula business led to net sales growth in the Nutrition category of 16%. Excluding the prior year benefit from retailer stocking due to the launch of Opill^®, our global brands delivered organic growth of +5.9% driven by actions to Streamline the portfolio and Strengthen investments on key brands with the highest return on investment opportunities. Investments and innovations to Strengthen the business through our 'High-Grow' brands remain on track to derive benefits in 2026. Collectively, the team delivered meaningful adjusted EPS growth and margin expansion versus the prior year."

Lockwood-Taylor concluded, "While macroenvironment uncertainty, including tariffs and consumer behavior, present new challenges, we have proactively engaged in extensive scenario planning to mitigate these impacts. Tariffs are expected to increase our global cost of goods sold, due primarily to Oral Care in CSCA. We plan to offset this impact through a combination of strategic price actions, insourcing to our U.S.-based manufacturing facilities and other supply chain actions. Though we are widening our 2025 topline growth ranges due to the current environment, our mitigation actions in addition to strong first quarter results, gives us the confidence to reaffirm all other 2025 financial targets. Our unique business model with 100+ molecules across 100% price point coverage and significant U.S. based manufacturing provides an advantage and sizable opportunities to deliver our essential self-care solutions to more customers and consumers in this evolving landscape."

Refer to Tables I through VII at the end of this press release for a reconciliation of non-GAAP adjustments to the current year and prior year periods and additional non-GAAP information. The Company's reported results are included in the attached Condensed Consolidated Statements of Operations, Balance Sheets and Statements of Cash Flows.

Project Energize

Perrigo has successfully transformed into a pure-play consumer self-care company and is embarking on the next stage of its self-care journey – evolving to One Perrigo. This evolution will create sustainable, value accretive growth by providing consumer needed self-care solutions at multiple price points.

As part of the Company's sustainable, value accretive growth strategy, the Company launched Project Energize – a global investment and efficiency program to drive the next evolution of capabilities and organizational agility – during the first quarter of 2024. This three-year program is expected to produce significant benefits in the Company's long-term business performance by enabling its One Perrigo growth strategy, increasing organizational agility and resetting the SG&A operating expense base. 

Project Energize is expected to deliver annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026. The Company expects $40 million to $60 million of these savings to be reinvested. Restructuring and related charges associated with these actions are estimated to be in the range of $140 million to $160 million, including $20 million to $40 million in investments to enhance capabilities, and are expected to be substantially incurred by the end of 2026. Since the beginning of the program in 2024, Project Energize has achieved gross annual savings of approximately $159 million with reinvestment of $20 million. Restructuring charges incurred by the Company over the same period in connection with Project Energize were $111 million.

Perrigo First Quarter 2025 Results from Continuing Operations

Net sales of $1.04 billion decreased 3.5%, or $38 million, due primarily to unfavorable impacts of 2.0% from divested businesses and exited product lines and 1.2% from currency translation.

Perrigo organic net sales were impacted by net pricing of (0.3)% and volume/mix of (0.1)%. Organic net sales declined 0.4% as 1) higher net sales in the Nutrition category, stemming from recovery in the infant formula business, 2) the Upper Respiratory category, due primarily to higher incidence levels of cough cold compared to the prior year and improved supply of a key product, and 3) the Healthy Lifestyle category led by strong momentum in smoking cessation brand NiQuitin^® were more than offset by 1) previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%, 2) the lack of a prior year benefit in the Women's Health category of 1.4% from initial retailer stocking of Opill^® which launched at the end of the quarter, and 3) lower net sales in the Digestive Health category, due to lower consumption of specific molecules.  

Reported gross profit of $392 million, increased $35 million, or 9.7%. Adjusted gross profit of $428 million increased $32 million, or 8.1%, as infant formula business recovery, Supply Chain Reinvention benefits and Project Energize savings more than offset lower U.S. OTC sales volumes in addition to divested businesses and exited product lines of $14 million. Organic adjusted gross profit grew 13.8% compared to the prior year quarter.

Reported gross margin was 37.6%, an increase of 450 basis points versus the prior year quarter. Adjusted gross margin expanded 440 basis points to 41.0%, due primarily to the same factors as adjusted gross profit. Divested businesses and exited product lines unfavorably impacted gross margin by 50 basis points.

Reported operating income was $47 million as compared to a loss of $(55) million in the prior year period. Adjusted operating income increased $54 million, or 57.6%, to $147 million driven by higher adjusted gross profit and Project Energize savings, partially offset by higher advertising and promotion investments, and divested businesses and exited product lines of $6 million. Organic adjusted operating income grew 71.0% compared to the prior year quarter.

Reported operating margin was 4.5%, an increase of 960 basis points versus the prior year quarter. Adjusted operating margin of 14.0%, expanded 550 basis points versus the prior year quarter due primarily to the same factors as adjusted operating income and included an unfavorable impact of 30 basis points from divested businesses and exited product lines.

Reported net income and EPS were breakeven compared to reported net income of $4 million, or $0.03 per diluted share, in the prior year period. First quarter 2025 adjusted net income was $83 million, or $0.60 per diluted share, compared to $40 million, or $0.29 per diluted share, in the prior year period, an increase of $0.31 or 106.9% per diluted share driven by the increase in adjusted operating income and lower interest expense due to lower total debt outstanding. First quarter 2025 adjusted diluted EPS included a higher tax rate compared to the prior year equating to $0.03 per adjusted diluted share, in addition to the impact of divested businesses, exited product lines and currency translation equating to an impact of $0.04 per adjusted diluted share.

First Quarter 2025 Business Segment Results from Continuing Operations

Consumer Self-Care Americas Segment (CSCA)

CSCA net sales of $621 million declined $23 million, or 3.6%, compared to the prior year.

Organic net sales decreased 3.6% as higher net sales 1) in the Nutrition category, stemming from recovery in the infant formula business, and 2) the Upper Respiratory category, due primarily to higher incidence levels of cough cold compared to the prior year, were more than offset by 1) previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 1.3%, 2) the lack of a prior year benefit in the Women's Health category of 2.3% from initial retailer stocking of Opill^® which launched at the end of the quarter, and 3) lower net sales in the Digestive Health category, due to lower consumption of specific molecules, principally proton pump inhibitors for heartburn.  

Reported gross profit of $200 million increased $47 million, or 30.3%. Adjusted gross profit increased $47 million, or 28.7%, to $210 million due primarily to infant formula business recovery and Supply Chain Reinvention benefits, which more than offset lower U.S. OTC sales volumes. 

Reported gross margin of 32.2% increased 840 basis points versus the prior year quarter. Adjusted gross margin increased 850 basis points to 33.8%, driven by the same factors as adjusted gross profit.

Reported operating income was $64 million compared to $16 million in the prior year quarter, an increase of $48 million, or 307.4%. Adjusted operating income increased $47 million, or 90.0%, to $100 million driven by higher adjusted gross profit as Project Energize savings offset higher advertising and promotion investments, primarily Opill^® and infant formula sales activation activities.

Reported operating margin of 10.3% increased 790 basis points versus the prior year quarter. Adjusted operating margin expanded 800 basis points to 16.1% driven by the same factors as adjusted operating income.

Consumer Self-Care International Segment (CSCI)

CSCI net sales of $423 million declined 3.4%, or $15 million, as organic net sales growth of 4.5% was more than offset by unfavorable impacts from divested businesses and exited product lines of 5.1%, and currency translation of 2.8%. 

Organic net sales growth was primarily driven by higher net sales of 1) 2.7% from the Upper Respiratory and Pain & Sleep-Aids categories, due primarily to higher seasonal sell-in activities, improved supply of a key product and slightly higher incidence levels of cough cold compared to the prior year, 2) 1.2% from the Healthy Lifestyle category led by strong momentum in smoking cessation brand NiQuitin^®, and 3) 0.6% from the Skin Care category led by brands Compeed^® and Sebamed^®, and earlier customer purchases ahead of the spring/summer season compared to the prior year. 

Reported gross profit of $192 million decreased $12 million, or 5.8%. Adjusted gross profit of $218 million decreased $15 million, or 6.3%, as prior strategic pricing actions and improved supply of key products were more than offset by cost of goods sold inflation, lower manufacturing productivity, $14 million from the impact of divested businesses and exited product lines, and $6 million from unfavorable currency translation. Organic adjusted gross profit grew 2.5% compared to the prior year quarter.

Reported gross margin of 45.4% decreased 120 basis points compared to the prior year. Adjusted gross margin declined 160 basis points to 51.4% driven primarily by the same factors as adjusted gross profit, partially offset by favorable brand mix due in part to improved supply of key products. Divested businesses and exited product lines had an unfavorable impact of 70 basis points.

Reported operating income was $40 million compared to $27 million in the prior year quarter, an increase of $13 million, or 49.1%. Adjusted operating income of $86 million was flat to the prior year quarter as the increase in organic adjusted gross profit and benefits from Project Energize were offset by $8 million from unfavorable currency translation, divested businesses and exited product lines.

Reported operating margin was 9.4%, a 330 basis points increase versus the prior year. Adjusted operating margin expanded 70 basis points to 20.4%, as operating leverage more than offset the unfavorable impact of 40 basis points from divested businesses and exited product lines.

Cash Flow and Balance Sheet

First quarter 2025 cash from operations was a loss of $(65) million compared to a loss of $(1) million in the prior year quarter as cash generated during the quarter was utilized to rebuild inventory in the infant formula business, settle outstanding litigation and cover Project Energize restructuring costs.

First quarter capital expenditures were $26 million while the Company returned $41 million to shareholders through dividends.

Cash and cash equivalents on the balance sheet as of March 29, 2025, were $410 million while total debt on the balance sheet was $3.63 billion.  

Known Impacts from Macroeconomic Uncertainty

Perrigo is the largest U.S. manufacturer of OTC self-care products by volume, which are produced by 11 U.S. manufacturing facilities with 85% of finished goods manufactured in the U.S., sourcing the majority of materials and components domestically. The Company has been closely following the evolving environment on global tariffs and is continuing to actively assess potential business implications.

Based on current assessments, excluding any potential impact from pharmaceutical tariffs that may cover ingredients used in the manufacturing of OTC products, the Company estimates a gross increase to global cost of goods sold in 2025 beginning in the fourth quarter of more than 1%, or approximately $30 million to $40 million, and approximately 5.5%, or approximately $145 million to $155 million, on a full-year basis (high-single digit percentage to CSCA), 80% of which stems from CSCA's Oral Care product category, as approximately 50% of our procured goods in the category are currently sourced from China. The Company plans to offset these impacts through a combination of strategic pricing actions, insourcing to its U.S.-based manufacturing facilities and other supply chain actions.

The Company believes that its unique business model with 100+ molecules across 100% price point coverage and significant U.S. based manufacturing provides an advantage and significant opportunities to deliver more essential self-care solutions to customers and consumers in this evolving landscape. As consumer prices are likely to rise, Perrigo's store brand and value brand offerings may benefit from shifting consumer behavior across the value spectrum in addition to further leveraging the Company's available U.S.-based manufacturing capacity in OTC, infant formula and oral care to better serve customers.

Please refer to Perrigo's latest Form 10-K for the year ended December 31, 2024 and 10-Q for the quarter ended March 29, 2025 for a detailed discussion of risk factors. 

Fiscal 2025 Outlook

The Company widened its fiscal year 2025 reported and organic net sales growth targets due primarily to macroeconomic uncertainty, and reaffirmed all other fiscal year 2025 financial targets: 

• Reported net sales growth of 0% to 3%, from 1% to 3%.
• Organic net sales growth of 1.5% to 4.5%, from 2.5% to 4.5%.
• Adjusted gross margin of approximately 40%.
• Adjusted operating margin of approximately 15%.
• Adjusted diluted earnings per share ("EPS") range of $2.90 to $3.10, equating to growth of 13% to 21%.
• Operating cash flow conversion to adjusted net income of approximately 100%.
• Free cash flow as a percentage of net sales of approximately 6%.
• Net leverage of approximately 3.5x adjusted EBITDA.

About Perrigo

Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com. 

Webcast and Conference Call Information

Perrigo has previously announced that the management will host an earnings conference call to discuss its first quarter 2025 financial results beginning at 08:30 A.M. (EST) Wednesday, May 7, 2025. The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Wednesday, May 7, until midnight Wednesday, May 14, 2025. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 04449#.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs); the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business, and the sale of our Hospital and Specialty Business and the risk that potential costs or liabilities incurred or retained in connection with those transactions may exceed our estimates or adversely affect our business or operations; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2024, and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-GAAP Measures

The Company cannot reconcile its expected organic net sales growth, adjusted gross margin, adjusted operating margin, adjusted diluted earnings per share to diluted earnings per share, operating cash flow conversion, adjusted net income, free cash flow or adjusted tax rate under "Fiscal 2025 Outlook" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include, but are not limited to uncertainty of non-recurring infant formula related charges and timing and amount of restructuring charges and the income tax effects of these items or other income tax-related events.

This press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the following non-GAAP financial measures referred to in this press release:

• net sales growth on an organic basis, which excludes acquisitions, divested businesses, exited product lines, and the impact of currency,
• adjusted gross profit,
• adjusted gross margin
• adjusted net income,
• adjusted operating income,
• adjusted diluted earnings per share,
• constant currency net sales growth,
• adjusted operating margin,
• and free cash flow.

These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies. The Company presents these non-GAAP financial measures in order to provide transparency to our investors because they are measures that management uses to assess both management performance and the financial performance of our operations and to allocate resources. In addition, management believes that these measures may assist investors with understanding and evaluating our initiatives to drive improved financial performance and enables investors to supplementally compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. While we have excluded certain of these items from historical non-GAAP financial measures, there is no guarantee that the items excluded from non-GAAP financial measures will not continue into future periods. For instance, we expect to continue to experience and report restructuring-related charges associated with continued execution of our strategic initiatives.

The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangible asset amortization excluded from these non-GAAP financial measures represents the entire amount recorded within the Company's GAAP financial statements and is excluded because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

Non-GAAP measures related to profit measurements, which may include adjusted net income, adjusted gross profit, adjusted operating income, adjusted diluted earnings per share, adjusted gross margin, adjusted operating margin, organic gross profit, organic operating income, free cash flow, and constant currency net sales, are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company also discloses net sales growth excluding the impact of currency on an organic basis. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past and present underlying operating results, and also facilitate analysis of the Company's operating performance and acquisition and divestiture trends.

A copy of this press release, including the reconciliations, is available on the Company's website at www.perrigo.com. 

Perrigo Contact

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications; (269) 686-3373; E-mail: [email protected]

Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications; (269) 686-3238, E-mail: [email protected]

 

 

 

 

 

 

 

  

 

CSCA First Quarter Primary Category Drivers:

• Upper Respiratory: Net sales of $138 million increased 5.8% due primarily to higher incidence levels of cough cold compared to the prior year quarter and higher net sales of the allergy products Nasonex^®, Triamcinolone Acetonide and Fluticasone. This growth was partially offset by previously disclosed net lost distribution of lower margin products.
• Nutrition: Net sales of $105 million increased 15.6% due primarily to a 19% increase in net sales of infant formula products driven by continuing store brand infant formula business recovery partially offset by lower net sales in contract manufacturing and lower Good Start^® brand sales to Canadian customers.
• Digestive Health: Net sales of $103 million decreased 15.7% due primarily to previously disclosed net lost distribution of lower margin products in U.S. Store Brand and lower consumption of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share gains. These impacts more than offset higher net sales of Polyethylene Glycol.
• Pain & Sleep-Aids: Net sales of $77 million decreased 7.2% due primarily to previously disclosed net lost distribution of lower margin products partially offset by new business awards.
• Healthy Lifestyle: Net sales of $70 million decreased 1.3% due primarily to lower category consumption of nicotine replacement therapy products, despite new distribution and market share gains.
• Oral Care: Net sales of $62 million decreased 4.2% due to lower distribution at specific retail customers and lower net sales of Plackers^® dental flossers, partially offset by higher net sales of store brands, particularly toothbrushes and flossers.
• Skin Care: Net sales of $49 million decreased 2.1% as growth in the Minoxidil franchise was more than offset by lower net sales of Mederma^® due to service issues that are anticipated to alleviate in the second quarter of 2025.
• Women's Health: Net sales of $15 million decreased 44.6% due primarily to initial retailer stocking of Opill^®, which launched at the end of the prior year quarter, of $15 million, or an impact to the category of 55.2%.
• Vitamins, Minerals, and Supplements ("VMS") and Other: Net sales of $2 million decreased 57.1%.

 

CSCI First Quarter Primary Category Drivers:

• Skin Care: Net sales of $112 million decreased 2.8%, or an increase of 0.5% excluding the impact of currency, including the impact of -1.8% from divested businesses and exited product lines. Growth was led by brands Compeed^® and Sebamed^®, and earlier customer purchases ahead of the spring/summer season compared to the prior year.
• Upper Respiratory: Net sales of $74 million increased 6.4%, or an increase of 9.1% excluding the impact of currency, due primarily to higher cough cold seasonal sell-in activities, improved supply of a key product and slightly higher incidence levels of cough cold compared to the prior year quarter. In addition, growth in allergy products, including Beconase^® and store brand allergy offerings, also added to growth.
• Healthy Lifestyle: Net sales of $67 million increased 3.0%, or an increase of 7.5% excluding the impact of currency, as strong momentum behind smoking cessation brand NiQuitin^® were more than offset by lower category consumption in weight loss, impacting XLS Medical^®, and parasites.
• Pain & Sleep-Aids: Net sales of $54 million increased 4.2%, or an increase of 5.1% excluding the impact of currency, as higher net sales of Solpadeine^®, due primarily to improved supply, were partially offset by 3.7% from divested businesses and exited product lines.
• VMS: Net sales of $38 million decreased 15.5%, or a decrease of 12.9% excluding the impact of currency, due primarily to deprioritization of the nutraceuticals portfolio.
• Women's Health: Net sales of $32 million increased 1.2%, or an increase of 4.0% excluding the impact of currency, due primarily to higher net sales of contraceptive products including ellaOne^®, driven by market share gains.
• Oral Care: Net sales of $23 million decreased 21.5%, or a decrease of 20.0% excluding the impact of currency, due primarily to lower net sales of store brand products.
• Digestive Health and Other: Net sales of $26 million decreased 22.3%, or a decrease of 20.8% excluding the impact of currency, primarily due to the divestiture of the HRA Pharma Rare Diseases Business, which was partially offset by higher net sales of store brand digestive health products.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-reports-first-quarter-2025-financial-results-from-continuing-operations-302448457.html

SOURCE Perrigo Company plc